Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  6. Summary
    002294   CNE100000FW8

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

(002294)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
27.87 27.55 27.55 26.77 27.94 Last
3718220 2736345 2466852 2956524 4161960 Volume
+1.31% -1.15% 0.00% -2.83% +4.37% Change
Estimated financial data (e)
Sales 2021 2 801 M 433 M 433 M
Net income 2021 714 M 110 M 110 M
Net cash position 2021 627 M 97,0 M 97,0 M
P/E ratio 2021 40,7x
Yield 2021 0,95%
Sales 2022 3 757 M 581 M 581 M
Net income 2022 910 M 141 M 141 M
Net cash position 2022 1 870 M 289 M 289 M
P/E ratio 2022 32,0x
Yield 2022 1,61%
Capitalization 31 148 M 4 817 M 4 818 M
EV / Sales 2021 10,9x
EV / Sales 2022 7,79x
Nbr of Employees 3 448
Free-Float 35,3%
More Financials
Company
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides two categories of products: pharmaceutical preparation and bulk drugs. The Company distributes its products within domestic market and to overseas markets. 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Shenzhen Salubris Pharmaceuticals Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
09/05Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity B..
CI
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candid..
MT
08/23Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the ..
CI
08/06SKILLFUL CRAFTSMAN EDUCATION TECHNOL : Names Dawei Chen as Chief Financial Offic..
MT
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for C..
CI
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
07/25SHENZHEN SALUBRIS PHARMACEUTICALS CO : 002294) intends to launch an Equity Buyba..
CI
07/02Salubris Biotechnology Co., Ltd. announced that it expects to receive CNY 263..
CI
06/22Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it has received CN..
CI
06/14ROSY METRO LIMITED acquired a 13.78% stake in M.A. Med Alliance S.A from Shen..
CI
04/19Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the ..
CI
03/30NORTAI International Ltd. announced that it expects to receive $80 million in..
CI
03/29Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the ..
CI
2020Shenzhen Salubris Biomedical Engineering Co., Ltd. announced that it has rece..
CI
More news
News in other languages on SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

- No features available -

More news
Chart SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Duration : Period :
Shenzhen Salubris Pharmaceuticals Co., Ltd. Technical Analysis Chart | 002294 | CNE100000FW8 | MarketScreener
Technical analysis trends SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 27,94 CNY
Average target price 22,60 CNY
Spread / Average Target -19,1%
EPS Revisions
Managers and Directors
Sing Ye General Manager & Director
Jun Liu Chief Financial Officer
Cheng Hai Ye Chairman
Ai Zhen Li Chairman-Supervisory Board
Ji Tang Member-Supervisory Board & Administrative Director